CN111704615B - 咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂 - Google Patents

咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂 Download PDF

Info

Publication number
CN111704615B
CN111704615B CN202010273331.8A CN202010273331A CN111704615B CN 111704615 B CN111704615 B CN 111704615B CN 202010273331 A CN202010273331 A CN 202010273331A CN 111704615 B CN111704615 B CN 111704615B
Authority
CN
China
Prior art keywords
compound
optionally substituted
ring
alkyl
substituent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010273331.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN111704615A (zh
Inventor
李菁
赵海波
王志伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beone Pharmaceutical Suzhou Co Ltd
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of CN111704615A publication Critical patent/CN111704615A/zh
Application granted granted Critical
Publication of CN111704615B publication Critical patent/CN111704615B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202010273331.8A 2017-09-08 2018-09-07 咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂 Active CN111704615B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/101058 2017-09-08
CN2017101058 2017-09-08
CN2017119373 2017-12-28
CNPCT/CN2017/119373 2017-12-28
CN2018086555 2018-05-11
CNPCT/CN2018/086555 2018-05-11
PCT/CN2018/104559 WO2019047915A1 (en) 2017-09-08 2018-09-07 IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS
CN201880057835.7A CN111051312A (zh) 2017-09-08 2018-09-07 咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880057835.7A Division CN111051312A (zh) 2017-09-08 2018-09-07 咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂

Publications (2)

Publication Number Publication Date
CN111704615A CN111704615A (zh) 2020-09-25
CN111704615B true CN111704615B (zh) 2023-02-17

Family

ID=65633578

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010273331.8A Active CN111704615B (zh) 2017-09-08 2018-09-07 咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂
CN201880057835.7A Pending CN111051312A (zh) 2017-09-08 2018-09-07 咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880057835.7A Pending CN111051312A (zh) 2017-09-08 2018-09-07 咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂

Country Status (21)

Country Link
US (3) US11220506B2 (https=)
EP (2) EP3679042B1 (https=)
JP (1) JP7128264B2 (https=)
KR (1) KR20200052297A (https=)
CN (2) CN111704615B (https=)
AU (2) AU2018328569B2 (https=)
BR (1) BR112020004500A2 (https=)
CA (1) CA3072842A1 (https=)
DK (1) DK3679042T3 (https=)
ES (1) ES2944658T3 (https=)
FI (1) FI3679042T3 (https=)
HU (1) HUE061898T2 (https=)
IL (1) IL272988B (https=)
MX (1) MX2020002630A (https=)
NZ (1) NZ761680A (https=)
PL (1) PL3679042T3 (https=)
PT (1) PT3679042T (https=)
SG (1) SG11202001286SA (https=)
TW (2) TWI817956B (https=)
WO (1) WO2019047915A1 (https=)
ZA (1) ZA202000875B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202233190A (zh) 2016-12-07 2022-09-01 英屬開曼群島商百濟神州有限公司 作為ＰＩ３Ｋδ抑制劑的咪唑並［１，５－Ａ］吡衍生物
TWI817956B (zh) 2017-09-08 2023-10-11 英屬開曼群島商百濟神州有限公司 咪唑並[1,5-A]吡嗪衍生物作爲PI3Kδ 抑制劑
JP2023503230A (ja) * 2019-11-21 2023-01-27 ベイジーン リミテッド Ｐｉ３キナーゼデルタ阻害剤との組合せで抗ｏｘ４０抗体を用いる癌治療の方法
JP2024521763A (ja) * 2021-05-27 2024-06-04 ベイジーン スウィッツァーランド ゲーエムベーハー Ｐｉ３ｋデルタ阻害剤の塩、その結晶形態、調製方法、及び使用
KR20240060647A (ko) * 2021-09-14 2024-05-08 베이진 엘티디 Btk 저해제와 pi3 키나제 저해제의 조합물을 이용하는 암 치료 방법

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005089352A (ja) * 2003-09-16 2005-04-07 Kissei Pharmaceut Co Ltd 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途
CN1898240A (zh) * 2003-10-15 2007-01-17 Osi制药公司 咪唑并吡嗪类酪氨酸激酶抑制剂
CA2922058A1 (en) * 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
AR102220A1 (es) * 2015-10-08 2017-02-15 Incyte Corp Imidazopiridinas e imidazopirazinas como inhibidores de lsd1
WO2017216292A1 (en) * 2016-06-16 2017-12-21 Janssen Pharmaceutica Nv Bicyclic pyridine, pyrazine, and pyrimidine derivatives as pi3k beta inhibitors
WO2018103688A1 (en) * 2016-12-07 2018-06-14 Beigene, Ltd. IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7659274B2 (en) * 2006-01-25 2010-02-09 Osi Pharmaceuticals, Inc. Unsaturated mTOR inhibitors
JP2012524063A (ja) * 2009-04-15 2012-10-11 アストラゼネカ・アクチエボラーグ アルツハイマー病などのグリコーゲンシンターゼキナーゼ３関連障害の治療に有用なイミダゾール置換ピリミジン
SG175195A1 (en) * 2009-04-16 2011-11-28 Ct Nac Investigaciones Oncologicas Cnio Imidazopyrazines for use as kinase inhibitors
CA2825028A1 (en) * 2011-02-09 2012-08-16 F. Hoffman-La Roche Ag Heterocyclic compounds as pi3 kinase inhibitors
EP2802586B1 (en) * 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituted imidazopyrazines as akt kinase inhibitors
EP2914296B2 (en) * 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
TWI687220B (zh) * 2013-03-01 2020-03-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
SG11201509842SA (en) 2013-05-30 2015-12-30 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
MA40596B1 (fr) * 2014-08-11 2021-12-31 Acerta Pharma Bv Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
TWI817956B (zh) 2017-09-08 2023-10-11 英屬開曼群島商百濟神州有限公司 咪唑並[1,5-A]吡嗪衍生物作爲PI3Kδ 抑制劑

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005089352A (ja) * 2003-09-16 2005-04-07 Kissei Pharmaceut Co Ltd 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途
CN1898240A (zh) * 2003-10-15 2007-01-17 Osi制药公司 咪唑并吡嗪类酪氨酸激酶抑制剂
CA2922058A1 (en) * 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
AR102220A1 (es) * 2015-10-08 2017-02-15 Incyte Corp Imidazopiridinas e imidazopirazinas como inhibidores de lsd1
WO2017216292A1 (en) * 2016-06-16 2017-12-21 Janssen Pharmaceutica Nv Bicyclic pyridine, pyrazine, and pyrimidine derivatives as pi3k beta inhibitors
WO2018103688A1 (en) * 2016-12-07 2018-06-14 Beigene, Ltd. IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Imidazo[1,2-a]pyrazines as novel PI3K inhibitors;Sonia Martinez Gonzalez,et al.;《Bioorganic & Medicinal Chemistry Letters》;20120128;第22卷;第1874-1878页 *
选择性PI3Kδ抑制剂的研究进展;辛敏行等;《中国药科大学学报》;20161231;第47卷(第05期);第503-510页 *

Also Published As

Publication number Publication date
MX2020002630A (es) 2020-07-20
NZ761680A (en) 2023-03-31
EP3679042A4 (en) 2021-01-13
CN111704615A (zh) 2020-09-25
JP7128264B2 (ja) 2022-08-30
BR112020004500A2 (pt) 2020-12-01
ES2944658T3 (es) 2023-06-23
AU2018328569B2 (en) 2023-07-27
US20220081447A1 (en) 2022-03-17
HUE061898T2 (hu) 2023-08-28
ZA202000875B (en) 2021-07-28
IL272988A (en) 2020-04-30
TW202336010A (zh) 2023-09-16
EP3679042B1 (en) 2023-03-01
PL3679042T3 (pl) 2023-09-04
AU2018328569A1 (en) 2020-02-27
US11905294B2 (en) 2024-02-20
JP2020534259A (ja) 2020-11-26
FI3679042T3 (fi) 2023-05-15
CA3072842A1 (en) 2019-03-14
DK3679042T3 (da) 2023-05-01
WO2019047915A1 (en) 2019-03-14
KR20200052297A (ko) 2020-05-14
TWI817956B (zh) 2023-10-11
PT3679042T (pt) 2023-05-18
EP3679042A1 (en) 2020-07-15
TW201920116A (zh) 2019-06-01
US11220506B2 (en) 2022-01-11
AU2023254925A1 (en) 2023-11-16
CN111051312A (zh) 2020-04-21
EP4219502A1 (en) 2023-08-02
IL272988B (en) 2022-08-01
SG11202001286SA (en) 2020-03-30
US20240150361A1 (en) 2024-05-09
US20200207774A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
CN111704615B (zh) 咪唑并[1,5-A]吡嗪衍生物作为PI3Kδ抑制剂
CN104918934B (zh) 3‑取代的吡唑及其作为dlk抑制剂的用途
CN108368116B (zh) Janus激酶抑制剂、其组合物及用途
US11725012B2 (en) Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors
HK40029158B (en) IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kδ INHIBITORS
HK40029158A (en) IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kδ INHIBITORS
HK40088309A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
HK40017128A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
EA040339B1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-а]ПИРАЗИНА КАК ИНГИБИТОРЫ PI3Kδ
HK40029822A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
HK40029822B (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
HK1258764B (en) Janus kinases inhibitors, compositions thereof and use thereof
HK1210166B (en) Fused tricyclic amide compounds as multiple kinase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40029158

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20251016

Address after: 215002 Jiangsu Province Suzhou City China (Shanghai) Pilot Free Trade Zone Suzhou Area Suzhou Industrial Park Jinhai Road 29.NO

Patentee after: Baiji Shenzhou (Suzhou) Biotechnology Co.,Ltd.

Country or region after: China

Address before: England Group

Patentee before: BEIGENE, Ltd.

Country or region before: Cayman Islands

TR01 Transfer of patent right